Pub Date : 2024-06-11eCollection Date: 2024-06-01DOI: 10.1093/jacamr/dlae089
Thi Anh Mai Pham, Tung Xuan Nguyen, Troung Nhat My, Lan Thi Le, Huyen Thi Vu, Ngoc Thi Bich Hoang, Dien M Tran, Linh Viet Nguyen, Phuc D Pham, Dennis Nurjadi, Flavie Goutard, Thirumalaisamy P Velavan, Van Anh Thi Dinh, Y M Gildas Hounmanou, Bent Jörgensen, Le Huu Song, Nhung T T Nguyen, Etienne Loire, Åse Östholm, Lennart E Nilsson, Tuyet Hanh T Tran, Phuc H Phan, Anders Dalsgaard, Mattias Larsson, Linus Olson, Håkan Hanberger
Objectives: To improve and rationalize the detection of carbapenemase-producing Enterobacterales (CPE) in rectal swabs in a high-prevalence and resource-constrained setting, addressing surveillance challenges typically encountered in laboratories with limited resources.
Methods: A point prevalence survey (PPS) was conducted on 15 August 2022, in a provincial children's hospital in northern Vietnam. Rectal swab samples of all admitted children were collected and plated on a selective medium for carbapenem-resistant Enterobacterales (CRE). Species identification and antimicrobial susceptibility testing (AST) were performed by MALDI-TOF, and VITEK2 XL and interpreted according to CLSI breakpoints (2022). Carbapenemases were detected by the carbapenem inactivation method (CIM) and quantitative real-time PCR (qRT-PCR).
Results: Rectal swab samples were obtained from 376 patients. Of 178 isolates growing on the CRE screening agar, 140 isolates were confirmed as Enterobacterales of which 118 (84.3%) isolates were resistant to meropenem and/or ertapenem. CIM and PCR showed that 90/118 (76.3%) were carbapenemase producers. Overall, 83/367 (22.6%) were colonized by CPE. Klebsiella pneumoniae, Escherichia coli and Enterobacter cloacae complex were the most common CPE detected, with NDM as the predominant carbapenemase (78/90; 86.7%). Phenotypic resistance to meropenem was the best predictor of CPE production (sensitivity 85.6%, specificity 100%) compared with ertapenem resistance (95.6% sensitivity, 36% specificity). CIM was 100% concordant with PCR in detecting carbapenemases.
Conclusions: These findings underscore the effectiveness of meropenem resistance as a robust indicator of the production of carbapenemases and the reliability of the CIM method to detect such carbapenemases in resource-limited settings where the performance of molecular methods is not possible.
{"title":"Evaluation of screening algorithms to detect rectal colonization with carbapenemase-producing Enterobacterales in a resource-limited setting.","authors":"Thi Anh Mai Pham, Tung Xuan Nguyen, Troung Nhat My, Lan Thi Le, Huyen Thi Vu, Ngoc Thi Bich Hoang, Dien M Tran, Linh Viet Nguyen, Phuc D Pham, Dennis Nurjadi, Flavie Goutard, Thirumalaisamy P Velavan, Van Anh Thi Dinh, Y M Gildas Hounmanou, Bent Jörgensen, Le Huu Song, Nhung T T Nguyen, Etienne Loire, Åse Östholm, Lennart E Nilsson, Tuyet Hanh T Tran, Phuc H Phan, Anders Dalsgaard, Mattias Larsson, Linus Olson, Håkan Hanberger","doi":"10.1093/jacamr/dlae089","DOIUrl":"10.1093/jacamr/dlae089","url":null,"abstract":"<p><strong>Objectives: </strong>To improve and rationalize the detection of carbapenemase-producing Enterobacterales (CPE) in rectal swabs in a high-prevalence and resource-constrained setting, addressing surveillance challenges typically encountered in laboratories with limited resources.</p><p><strong>Methods: </strong>A point prevalence survey (PPS) was conducted on 15 August 2022, in a provincial children's hospital in northern Vietnam. Rectal swab samples of all admitted children were collected and plated on a selective medium for carbapenem-resistant Enterobacterales (CRE). Species identification and antimicrobial susceptibility testing (AST) were performed by MALDI-TOF, and VITEK2 XL and interpreted according to CLSI breakpoints (2022). Carbapenemases were detected by the carbapenem inactivation method (CIM) and quantitative real-time PCR (qRT-PCR).</p><p><strong>Results: </strong>Rectal swab samples were obtained from 376 patients. Of 178 isolates growing on the CRE screening agar, 140 isolates were confirmed as Enterobacterales of which 118 (84.3%) isolates were resistant to meropenem and/or ertapenem. CIM and PCR showed that 90/118 (76.3%) were carbapenemase producers. Overall, 83/367 (22.6%) were colonized by CPE. <i>Klebsiella pneumoniae</i>, <i>Escherichia coli</i> and <i>Enterobacter cloacae</i> complex were the most common CPE detected, with NDM as the predominant carbapenemase (78/90; 86.7%). Phenotypic resistance to meropenem was the best predictor of CPE production (sensitivity 85.6%, specificity 100%) compared with ertapenem resistance (95.6% sensitivity, 36% specificity). CIM was 100% concordant with PCR in detecting carbapenemases.</p><p><strong>Conclusions: </strong>These findings underscore the effectiveness of meropenem resistance as a robust indicator of the production of carbapenemases and the reliability of the CIM method to detect such carbapenemases in resource-limited settings where the performance of molecular methods is not possible.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"6 3","pages":"dlae089"},"PeriodicalIF":3.7,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11166082/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141305878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-11eCollection Date: 2024-06-01DOI: 10.1093/jacamr/dlae093
Achiraya Chanapal, Hung-Yung Cheng, Helen Lambert, Wenjuan Cong
Background: The prescribing of antibiotics to treat COVID-19 patients has been observed to occur frequently, often without clear justification. This trend raises concerns that it may have exacerbated antimicrobial resistance (AMR). Despite longstanding concerns over AMR in Southeast Asian countries, data on this issue are notably lacking.
Objectives: To explore the impact of COVID-19 on antibiotic prescribing, bacterial infection prevalence and common resistant pathogens in COVID-19 inpatients.
Methods: We searched PubMed, EMBASE, Web of Science and ThaiJO (a Thai academic database) to identify studies conducted in ASEAN member countries and published between December 2019 and March 2023. Screening and data extraction were done by two independent reviewers, with results synthesized using random-effects meta-analyses and descriptive statistical analyses. This review was registered with PROSPERO (CRD42023454337).
Results: Of the 29 studies (19 750 confirmed COVID-19 cases) included for final analysis, the antibiotic prescribing rate was 62.0% (95%CI: 46.0%-76.0%) with a prescribing rate of 58.0% (21.0%-91.0%) in mild/moderate cases versus 91.0% (82.0%-98.0%) in severe/critical cases. Notably, 80.5% of antibiotics prescribed fall under the WHO AWaRe 'Watch' list, followed by 'Access' at 18.4% and 'Reserve' at 1.0%. The reported bacterial infection prevalence was 16.0% (7.0%-29.0%), with Acinetobacter baumannii being the most common resistant bacterium at 7.7%. Singapore was notable for its lower antibiotic prescribing rate of 17.0% and a lower bacterial infection rate of 10.0%.
Conclusions: High antibiotic prescribing rates, disproportionate to bacterial infections and varying practices for COVID-19 inpatients across countries highlight the urgent need for this region to collaborate to tackle and mitigate AMR.
{"title":"Antibiotic prescribing and bacterial infection in COVID-19 inpatients in Southeast Asia: a systematic review and meta-analysis.","authors":"Achiraya Chanapal, Hung-Yung Cheng, Helen Lambert, Wenjuan Cong","doi":"10.1093/jacamr/dlae093","DOIUrl":"10.1093/jacamr/dlae093","url":null,"abstract":"<p><strong>Background: </strong>The prescribing of antibiotics to treat COVID-19 patients has been observed to occur frequently, often without clear justification. This trend raises concerns that it may have exacerbated antimicrobial resistance (AMR). Despite longstanding concerns over AMR in Southeast Asian countries, data on this issue are notably lacking.</p><p><strong>Objectives: </strong>To explore the impact of COVID-19 on antibiotic prescribing, bacterial infection prevalence and common resistant pathogens in COVID-19 inpatients.</p><p><strong>Methods: </strong>We searched PubMed, EMBASE, Web of Science and ThaiJO (a Thai academic database) to identify studies conducted in ASEAN member countries and published between December 2019 and March 2023. Screening and data extraction were done by two independent reviewers, with results synthesized using random-effects meta-analyses and descriptive statistical analyses. This review was registered with PROSPERO (CRD42023454337).</p><p><strong>Results: </strong>Of the 29 studies (19 750 confirmed COVID-19 cases) included for final analysis, the antibiotic prescribing rate was 62.0% (95%CI: 46.0%-76.0%) with a prescribing rate of 58.0% (21.0%-91.0%) in mild/moderate cases versus 91.0% (82.0%-98.0%) in severe/critical cases. Notably, 80.5% of antibiotics prescribed fall under the WHO AWaRe 'Watch' list, followed by 'Access' at 18.4% and 'Reserve' at 1.0%. The reported bacterial infection prevalence was 16.0% (7.0%-29.0%), with <i>Acinetobacter baumannii</i> being the most common resistant bacterium at 7.7%. Singapore was notable for its lower antibiotic prescribing rate of 17.0% and a lower bacterial infection rate of 10.0%.</p><p><strong>Conclusions: </strong>High antibiotic prescribing rates, disproportionate to bacterial infections and varying practices for COVID-19 inpatients across countries highlight the urgent need for this region to collaborate to tackle and mitigate AMR.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"6 3","pages":"dlae093"},"PeriodicalIF":3.7,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11166085/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141305876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-11eCollection Date: 2024-06-01DOI: 10.1093/jacamr/dlae091
Tomefa E Asempa, David P Nicolau
{"title":"Comment on: Comparison of carbapenem MIC for NDM-producing Enterobacterales by different AST methods: considerations for media composition.","authors":"Tomefa E Asempa, David P Nicolau","doi":"10.1093/jacamr/dlae091","DOIUrl":"10.1093/jacamr/dlae091","url":null,"abstract":"","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"6 3","pages":"dlae091"},"PeriodicalIF":3.7,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11166084/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141305877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-11eCollection Date: 2024-06-01DOI: 10.1093/jacamr/dlae094
Steward Mudenda, Karen Mubanga Mulenga, Ruth Nyirongo, Billy Chabalenge, Chikwanda Chileshe, Victor Daka, Ethel M'kandawire, Elimas Jere, John Bwalya Muma
Background: The irrational use of antibiotics in humans and livestock has contributed to the emergence of antimicrobial resistance (AMR). This study investigated the commonly sold and dispensed antibiotics for prophylaxis in broiler chickens in pharmacy and agro-veterinary shop personnel in the Lusaka District of Zambia.
Methods: This cross-sectional study was conducted from August 2023 to October 2023 among 200 veterinary medicine dispensers in the Lusaka District of Zambia using a simulated farmer or mystery shopper approach. Data analysis was performed using IBM Statistical Package for Social Sciences version 23.0.
Results: Out of the 200 medicine outlets investigated, 23 (11.5%) were agro-veterinary shops, while 177 (88.5%) were community pharmacies. A total of 165 community pharmacies and agro-veterinary shops provided veterinary services in the Lusaka District and sold medicines without prescription giving a 100% non-prescription sale. Of the 178 medicines dispensed for prophylaxis, 88.5% were antibiotics, while 13.5% were vitamins. The most dispensed antibiotic drug for prophylaxis in broiler chickens was oxytetracycline (30.34%), amoxicillin (17.98%) and gentamicin/doxycycline (10.67%).
Conclusions: This study revealed a high sale and dispensing of antibiotics for prophylaxis in broiler chickens of which oxytetracycline, amoxicillin and gentamicin/doxycycline were commonly dispensed. There is a need for increased regulatory enforcement of selling antibiotics without a prescription as this may predispose poultry to the development of AMR and possible transmission of superbugs to humans and the environment. Educational interventions should be provided to community pharmacy and agro-veterinary personnel on adhering to antimicrobial stewardship practices when dispensing poultry antibiotics.
{"title":"Non-prescription sale and dispensing of antibiotics for prophylaxis in broiler chickens in Lusaka District, Zambia: findings and implications on one health.","authors":"Steward Mudenda, Karen Mubanga Mulenga, Ruth Nyirongo, Billy Chabalenge, Chikwanda Chileshe, Victor Daka, Ethel M'kandawire, Elimas Jere, John Bwalya Muma","doi":"10.1093/jacamr/dlae094","DOIUrl":"10.1093/jacamr/dlae094","url":null,"abstract":"<p><strong>Background: </strong>The irrational use of antibiotics in humans and livestock has contributed to the emergence of antimicrobial resistance (AMR). This study investigated the commonly sold and dispensed antibiotics for prophylaxis in broiler chickens in pharmacy and agro-veterinary shop personnel in the Lusaka District of Zambia.</p><p><strong>Methods: </strong>This cross-sectional study was conducted from August 2023 to October 2023 among 200 veterinary medicine dispensers in the Lusaka District of Zambia using a simulated farmer or mystery shopper approach. Data analysis was performed using IBM Statistical Package for Social Sciences version 23.0.</p><p><strong>Results: </strong>Out of the 200 medicine outlets investigated, 23 (11.5%) were agro-veterinary shops, while 177 (88.5%) were community pharmacies. A total of 165 community pharmacies and agro-veterinary shops provided veterinary services in the Lusaka District and sold medicines without prescription giving a 100% non-prescription sale. Of the 178 medicines dispensed for prophylaxis, 88.5% were antibiotics, while 13.5% were vitamins. The most dispensed antibiotic drug for prophylaxis in broiler chickens was oxytetracycline (30.34%), amoxicillin (17.98%) and gentamicin/doxycycline (10.67%).</p><p><strong>Conclusions: </strong>This study revealed a high sale and dispensing of antibiotics for prophylaxis in broiler chickens of which oxytetracycline, amoxicillin and gentamicin/doxycycline were commonly dispensed. There is a need for increased regulatory enforcement of selling antibiotics without a prescription as this may predispose poultry to the development of AMR and possible transmission of superbugs to humans and the environment. Educational interventions should be provided to community pharmacy and agro-veterinary personnel on adhering to antimicrobial stewardship practices when dispensing poultry antibiotics.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"6 3","pages":"dlae094"},"PeriodicalIF":3.7,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11166086/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141305879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: The first objective of the Global Action Plan on antimicrobial resistance (AMR) is to improve awareness and understanding of AMR through effective communication, education and training. Towards this several efforts have been made to create AMR awareness resources. The aim of these resources is to inform the public about responsible antibiotic use and drive positive behavioural change. Digital media and specifically games can serve as unique innovative platforms in public communication programmes.
Objectives: This study focuses on compiling and evaluating game-based AMR resources. Recognizing the engaging and creative potential of games as learning tools, the primary objective of this study was to identify games that can be used, individually or in combination depending on their unique focus and gameplay experience, for AMR awareness. Furthermore, games are evaluated on five objective criteria and recommendations are made towards further development of gaming resources towards AMR awareness.
Methods: Meticulous curation was performed to mine information, education and communication resources, with a primary focus on games for AMR awareness and evaluating them based on game design and gameplay, AMR content and learning, engagement and replay appeal, learning outcomes, and level of difficulty and challenges.
Results: In this study, we selected 12 AMR games. Our evaluations, spanning various gamification elements and interactive parameters, informed recommendations for future AMR resource development, including multilevel game design, varied graphics, simple-to-understand rules, sustained challenge and a sense of reward, among others.
Conclusions: This study generated the first-ever comprehensive catalogue of AMR games that may assist public communication programmes for AMR awareness. Evaluation of these games led to actionable design recommendations for future resources towards effective communication of AMR complexity, enhanced learning and awareness.
背景:抗菌药物耐药性(AMR)全球行动计划的第一个目标是通过有效的沟通、教育和培训,提高人们对抗菌药物耐药性的认识和了解。为实现这一目标,已经做出了多项努力,以创建提高对抗生素耐药性认识的资源。这些资源的目的是让公众了解负责任地使用抗生素,并推动积极的行为改变。数字媒体,特别是游戏,可以成为公众宣传计划中独特的创新平台:本研究的重点是汇编和评估基于游戏的 AMR 资源。认识到游戏作为学习工具所具有的参与性和创造性潜力,本研究的主要目标是确定可单独使用或组合使用的游戏,具体取决于其独特的侧重点和游戏体验,以提高对 AMR 的认识。此外,还根据五项客观标准对游戏进行了评估,并就进一步开发游戏资源以提高 AMR 意识提出了建议:方法:我们对信息、教育和交流资源进行了细致的整理,主要关注提高 AMR 意识的游戏,并根据游戏设计和游戏性、AMR 内容和学习、参与度和重玩吸引力、学习成果以及难度和挑战水平对其进行评估:在这项研究中,我们选择了 12 款 AMR 游戏。我们的评估涵盖了各种游戏化元素和互动参数,为今后的 AMR 资源开发提供了建议,包括多层次游戏设计、多样化图形、简单易懂的规则、持续挑战和奖励感等:这项研究首次编制了一份全面的 AMR 游戏目录,可帮助公众开展提高 AMR 意识的宣传计划。通过对这些游戏的评估,为今后有效传播 AMR 的复杂性、加强学习和提高认识的资源提出了可行的设计建议。
{"title":"The role of gaming for information, education and communication of AMR: full review of online education resources.","authors":"Romita Trehan, Raphael Goujet, Tina Sharma, Abhinav Vats, Nidhiben Patel, Anshu Bhardwaj","doi":"10.1093/jacamr/dlae080","DOIUrl":"10.1093/jacamr/dlae080","url":null,"abstract":"<p><strong>Background: </strong>The first objective of the Global Action Plan on antimicrobial resistance (AMR) is to improve awareness and understanding of AMR through effective communication, education and training. Towards this several efforts have been made to create AMR awareness resources. The aim of these resources is to inform the public about responsible antibiotic use and drive positive behavioural change. Digital media and specifically games can serve as unique innovative platforms in public communication programmes.</p><p><strong>Objectives: </strong>This study focuses on compiling and evaluating game-based AMR resources. Recognizing the engaging and creative potential of games as learning tools, the primary objective of this study was to identify games that can be used, individually or in combination depending on their unique focus and gameplay experience, for AMR awareness. Furthermore, games are evaluated on five objective criteria and recommendations are made towards further development of gaming resources towards AMR awareness.</p><p><strong>Methods: </strong>Meticulous curation was performed to mine information, education and communication resources, with a primary focus on games for AMR awareness and evaluating them based on game design and gameplay, AMR content and learning, engagement and replay appeal, learning outcomes, and level of difficulty and challenges.</p><p><strong>Results: </strong>In this study, we selected 12 AMR games. Our evaluations, spanning various gamification elements and interactive parameters, informed recommendations for future AMR resource development, including multilevel game design, varied graphics, simple-to-understand rules, sustained challenge and a sense of reward, among others.</p><p><strong>Conclusions: </strong>This study generated the first-ever comprehensive catalogue of AMR games that may assist public communication programmes for AMR awareness. Evaluation of these games led to actionable design recommendations for future resources towards effective communication of AMR complexity, enhanced learning and awareness.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"6 3","pages":"dlae080"},"PeriodicalIF":3.7,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11165311/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141305880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-06eCollection Date: 2024-06-01DOI: 10.1093/jacamr/dlae085
Timo J B Van Eldijk, Eleanor A Sheridan, Guillaume Martin, Franz J Weissing, Oscar P Kuipers, G Sander Van Doorn
Objectives: Environmental conditions can influence mutation rates in bacteria. Fever is a common response to infection that alters the growth conditions of infecting bacteria. Here we examine how a temperature change, such as is associated with fever, affects the mutation rate towards antibiotic resistance.
Methods: We used a fluctuation test to assess the mutation rate towards antibiotic resistance in Escherichia coli at two different temperatures: 37°C (normal temperature) and 40°C (fever temperature). We performed this measurement for three different antibiotics with different modes of action: ciprofloxacin, rifampicin and ampicillin.
Results: In all cases, the mutation rate towards antibiotic resistance turned out to be temperature dependent, but in different ways. Fever temperatures led to a reduced mutation rate towards ampicillin resistance and an elevated mutation rate towards ciprofloxacin and rifampicin resistance.
Conclusions: This study shows that the mutation rate towards antibiotic resistance is impacted by a small change in temperature, such as associated with fever. This opens a new avenue to mitigate the emergence of antibiotic resistance by coordinating the choice of an antibiotic with the decision of whether or not to suppress fever when treating a patient. Hence, optimized combinations of antibiotics and fever suppression strategies may be a new weapon in the battle against antibiotic resistance.
{"title":"Temperature dependence of the mutation rate towards antibiotic resistance.","authors":"Timo J B Van Eldijk, Eleanor A Sheridan, Guillaume Martin, Franz J Weissing, Oscar P Kuipers, G Sander Van Doorn","doi":"10.1093/jacamr/dlae085","DOIUrl":"10.1093/jacamr/dlae085","url":null,"abstract":"<p><strong>Objectives: </strong>Environmental conditions can influence mutation rates in bacteria. Fever is a common response to infection that alters the growth conditions of infecting bacteria. Here we examine how a temperature change, such as is associated with fever, affects the mutation rate towards antibiotic resistance.</p><p><strong>Methods: </strong>We used a fluctuation test to assess the mutation rate towards antibiotic resistance in <i>Escherichia coli</i> at two different temperatures: 37°C (normal temperature) and 40°C (fever temperature). We performed this measurement for three different antibiotics with different modes of action: ciprofloxacin, rifampicin and ampicillin.</p><p><strong>Results: </strong>In all cases, the mutation rate towards antibiotic resistance turned out to be temperature dependent, but in different ways. Fever temperatures led to a reduced mutation rate towards ampicillin resistance and an elevated mutation rate towards ciprofloxacin and rifampicin resistance.</p><p><strong>Conclusions: </strong>This study shows that the mutation rate towards antibiotic resistance is impacted by a small change in temperature, such as associated with fever. This opens a new avenue to mitigate the emergence of antibiotic resistance by coordinating the choice of an antibiotic with the decision of whether or not to suppress fever when treating a patient. Hence, optimized combinations of antibiotics and fever suppression strategies may be a new weapon in the battle against antibiotic resistance.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"6 3","pages":"dlae085"},"PeriodicalIF":3.7,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11154133/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141283728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-06eCollection Date: 2024-06-01DOI: 10.1093/jacamr/dlae087
Ángel Rodríguez-Villodres, Esperanza Lepe-Balsalobre, José Manuel Ortiz De La Rosa, Salvador Giner Almaraz, Elisa González De Herrero, Emilia Cercenado, Sergio García-Fernández, Rafael Benito, Ricardo Ponz Mir, Rafael Cantón, José Antonio Lepe
Objectives: To analyse the susceptibility profile to cefepime, carbapenems and new β-lactam/β-lactamase inhibitor combinations in Enterobacter cloacae complex and Klebsiella aerogenes isolated from intra-abdominal, urinary, respiratory and bloodstream infections in the SMART (Study for Monitoring Antimicrobial Resistance Trends) surveillance study in Spain.
Methods: The susceptibilities of 759 isolates (473 E. cloacae complex and 286 K. aerogenes) collected in 11 Spanish hospitals from 2016 to 2022 were analysed following the EUCAST 2023 criteria. Molecular characterization looking for β-lactamase genes was performed through PCR and DNA sequencing analysis.
Results: E. cloacae complex showed resistance to third-generation cephalosporins in 25% of the cases, whereas K. aerogenes was resistant in 35%. Regarding cefepime, resistance in E. cloacae was higher (10%) than in K. aerogenes (2%). Carbapenems showed >85% activity in both microorganisms. Ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam had good activity against these microorganisms (>95%). In contrast, the activity of ceftolozane/tazobactam was lower (80%). A high proportion of the isolates resistant to new β-lactam/β-lactamase inhibitor combinations carried a carbapenemase, mainly OXA-48-like and VIM-1.
Conclusions: Ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam show high activity against both E. cloacae complex and K. aerogenes isolates recovered in the SMART-Spain study. In contrast, differences have been found in the case of cefepime, showing more activity against K. aerogenes than E. cloacae complex. These results are useful for antimicrobial stewardship programmes and for the implementation of local and national guidelines.
{"title":"Activity of cefepime, carbapenems and new β-lactam/β-lactamase inhibitor combinations on <i>Enterobacter cloacae</i> complex and <i>Klebsiella aerogenes</i> in Spain (SMART 2016-2022).","authors":"Ángel Rodríguez-Villodres, Esperanza Lepe-Balsalobre, José Manuel Ortiz De La Rosa, Salvador Giner Almaraz, Elisa González De Herrero, Emilia Cercenado, Sergio García-Fernández, Rafael Benito, Ricardo Ponz Mir, Rafael Cantón, José Antonio Lepe","doi":"10.1093/jacamr/dlae087","DOIUrl":"10.1093/jacamr/dlae087","url":null,"abstract":"<p><strong>Objectives: </strong>To analyse the susceptibility profile to cefepime, carbapenems and new β-lactam/β-lactamase inhibitor combinations in <i>Enterobacter cloacae</i> complex and <i>Klebsiella aerogenes</i> isolated from intra-abdominal, urinary, respiratory and bloodstream infections in the SMART (Study for Monitoring Antimicrobial Resistance Trends) surveillance study in Spain.</p><p><strong>Methods: </strong>The susceptibilities of 759 isolates (473 <i>E. cloacae</i> complex and 286 <i>K. aerogenes</i>) collected in 11 Spanish hospitals from 2016 to 2022 were analysed following the EUCAST 2023 criteria. Molecular characterization looking for β-lactamase genes was performed through PCR and DNA sequencing analysis.</p><p><strong>Results: </strong><i>E. cloacae</i> complex showed resistance to third-generation cephalosporins in 25% of the cases, whereas <i>K. aerogenes</i> was resistant in 35%. Regarding cefepime, resistance in <i>E. cloacae</i> was higher (10%) than in <i>K. aerogenes</i> (2%). Carbapenems showed >85% activity in both microorganisms. Ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam had good activity against these microorganisms (>95%). In contrast, the activity of ceftolozane/tazobactam was lower (80%). A high proportion of the isolates resistant to new β-lactam/β-lactamase inhibitor combinations carried a carbapenemase, mainly OXA-48-like and VIM-1.</p><p><strong>Conclusions: </strong>Ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam show high activity against both <i>E. cloacae</i> complex and <i>K. aerogenes</i> isolates recovered in the SMART-Spain study. In contrast, differences have been found in the case of cefepime, showing more activity against <i>K. aerogenes</i> than <i>E. cloacae</i> complex. These results are useful for antimicrobial stewardship programmes and for the implementation of local and national guidelines.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"6 3","pages":"dlae087"},"PeriodicalIF":3.7,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11154015/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141283727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Ceftriaxone is administered in regimens of either 2 g once-daily or 1 g twice-daily for the treatment of pneumonia caused by Streptococcus pneumoniae. Previous clinical study suggests the 2 g once-daily regimen is more effective, but comparison of antimicrobial efficacy between are lacking.
Objectives: To assess the antimicrobial efficacy of these two ceftriaxone regimens against S. pneumoniae using a murine model of pneumonia.
Methods: The study employed three S. pneumoniae isolates with ceftriaxone MICs of 1, 2 and 4 mg/L and two human-simulated regimens based on the blood concentration of ceftriaxone (1 g twice-daily and 2 g once-daily). Antimicrobial activity was quantified based on the change in bacterial counts (Δlog10 cfu/lungs) observed in treated mice after 24 h, relative to the control mice at 0 h.
Results: The human-simulated 2 g once-daily regimen of ceftriaxone exhibited significantly higher antimicrobial activity against S. pneumoniae isolates with MICs of 1 and 2 mg/L compared with the 1 g twice-daily regimen (1 mg/L, -5.14 ± 0.19 Δlog10 cfu/lungs versus -3.47 ± 0.17 Δlog10 cfu/lungs, P < 0.001; 2 mg/L, -3.41 ± 0.31 Δ log10 cfu/lungs versus -2.71 ± 0.37 Δlog10 cfu/lungs, P = 0.027). No significant difference in antimicrobial activity was observed against the S. pneumoniae isolate with a MIC of 4 mg/L between the two regimens (-0.33 ± 0.18 Δlog10 cfu/lungs versus -0.42 ± 0.37 Δlog10 cfu/lungs, P = 0.684).
Conclusion: 2 g once-daily regimen of ceftriaxone is more effective for treating pneumonia caused by S. pneumoniae, with MICs of ≤2 mg/L.
{"title":"Evaluating the antimicrobial efficacy of ceftriaxone regimens: 1 g twice daily versus 2 g once daily in a murine model of <i>Streptococcus pneumoniae</i> pneumonia.","authors":"Hideo Kato, Mao Hagihara, Shun-Ichi Hiramatsu, Hiroyuki Suematsu, Naoya Nishiyama, Nobuhiro Asai, Hiroshige Mikamo, Kazuko Yamamoto, Takuya Iwamoto","doi":"10.1093/jacamr/dlae092","DOIUrl":"10.1093/jacamr/dlae092","url":null,"abstract":"<p><strong>Background: </strong>Ceftriaxone is administered in regimens of either 2 g once-daily or 1 g twice-daily for the treatment of pneumonia caused by <i>Streptococcus pneumoniae</i>. Previous clinical study suggests the 2 g once-daily regimen is more effective, but comparison of antimicrobial efficacy between are lacking.</p><p><strong>Objectives: </strong>To assess the antimicrobial efficacy of these two ceftriaxone regimens against <i>S. pneumoniae</i> using a murine model of pneumonia.</p><p><strong>Methods: </strong>The study employed three <i>S. pneumoniae</i> isolates with ceftriaxone MICs of 1, 2 and 4 mg/L and two human-simulated regimens based on the blood concentration of ceftriaxone (1 g twice-daily and 2 g once-daily). Antimicrobial activity was quantified based on the change in bacterial counts (Δlog<sub>10</sub> cfu/lungs) observed in treated mice after 24 h, relative to the control mice at 0 h.</p><p><strong>Results: </strong>The human-simulated 2 g once-daily regimen of ceftriaxone exhibited significantly higher antimicrobial activity against <i>S. pneumoniae</i> isolates with MICs of 1 and 2 mg/L compared with the 1 g twice-daily regimen (1 mg/L, -5.14 ± 0.19 Δlog<sub>10</sub> cfu/lungs versus -3.47 ± 0.17 Δlog<sub>10</sub> cfu/lungs, <i>P</i> < 0.001; 2 mg/L, -3.41 ± 0.31 Δ log<sub>10</sub> cfu/lungs versus -2.71 ± 0.37 Δlog<sub>10</sub> cfu/lungs, <i>P</i> = 0.027). No significant difference in antimicrobial activity was observed against the <i>S. pneumoniae</i> isolate with a MIC of 4 mg/L between the two regimens (-0.33 ± 0.18 Δlog<sub>10</sub> cfu/lungs versus -0.42 ± 0.37 Δlog<sub>10</sub> cfu/lungs, <i>P</i> = 0.684).</p><p><strong>Conclusion: </strong>2 g once-daily regimen of ceftriaxone is more effective for treating pneumonia caused by <i>S. pneumoniae,</i> with MICs of ≤2 mg/L.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"6 3","pages":"dlae092"},"PeriodicalIF":3.7,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11148390/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141247529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-04eCollection Date: 2024-06-01DOI: 10.1093/jacamr/dlae086
William J Jowsey, Gregory M Cook, Matthew B McNeil
Background: A limited ability to eliminate drug-resistant strains of Mycobacterium tuberculosis is a major contributor to the morbidity of TB. Complicating this problem, little is known about how drug resistance-conferring mutations alter the ability of M. tuberculosis to tolerate antibiotic killing. Here, we investigated if drug-resistant strains of M. tuberculosis have an altered ability to tolerate killing by cell wall-targeting inhibitors.
Methods: Bacterial killing and MIC assays were used to test for antibiotic tolerance and synergy against a panel of drug-resistant M. tuberculosis strains.
Results: Our results demonstrate that vancomycin and thioacetazone exhibit increased killing of diverse drug-resistant strains. Mutations in mmaA4 and mmpL3 increased vancomycin killing, which was consistent with vancomycin synergizing with thioacetazone and MmpL3-targeting inhibitors. In contrast, mutations in the mce1 operon conferred tolerance to vancomycin.
Conclusions: Overall, this work demonstrates how drug-resistant strains experience perturbations in cell-wall production that alters their tolerance to killing by cell wall-targeting inhibitors.
背景:消除结核分枝杆菌耐药菌株的能力有限,是导致结核病发病率的主要原因。使这一问题更加复杂的是,人们对耐药性突变如何改变结核分枝杆菌耐受抗生素杀灭的能力知之甚少。在此,我们研究了耐药菌株是否改变了耐受细胞壁靶向抑制剂杀灭的能力:方法:使用杀菌和 MIC 试验来检测抗生素对耐药结核杆菌株的耐受性和协同作用:结果:我们的研究结果表明,万古霉素和硫代乙酰唑酮对多种耐药菌株的杀灭作用增强。mmaA4 和 mmpL3 的突变增加了万古霉素的杀伤力,这与万古霉素与硫代乙酰唑酮和 MmpL3 靶向抑制剂的协同作用是一致的。与此相反,mce1操作子的突变则赋予了万古霉素耐受性:总之,这项工作证明了耐药菌株如何经历细胞壁生产的扰动,从而改变它们对细胞壁靶向抑制剂的耐受性。
{"title":"Antibiotic resistance in <i>Mycobacterium tuberculosis</i> alters tolerance to cell wall-targeting inhibitors.","authors":"William J Jowsey, Gregory M Cook, Matthew B McNeil","doi":"10.1093/jacamr/dlae086","DOIUrl":"10.1093/jacamr/dlae086","url":null,"abstract":"<p><strong>Background: </strong>A limited ability to eliminate drug-resistant strains of <i>Mycobacterium tuberculosis</i> is a major contributor to the morbidity of TB. Complicating this problem, little is known about how drug resistance-conferring mutations alter the ability of <i>M. tuberculosis</i> to tolerate antibiotic killing. Here, we investigated if drug-resistant strains of <i>M. tuberculosis</i> have an altered ability to tolerate killing by cell wall-targeting inhibitors.</p><p><strong>Methods: </strong>Bacterial killing and MIC assays were used to test for antibiotic tolerance and synergy against a panel of drug-resistant <i>M. tuberculosis</i> strains.</p><p><strong>Results: </strong>Our results demonstrate that vancomycin and thioacetazone exhibit increased killing of diverse drug-resistant strains. Mutations in <i>mmaA4</i> and <i>mmpL3</i> increased vancomycin killing, which was consistent with vancomycin synergizing with thioacetazone and MmpL3-targeting inhibitors. In contrast, mutations in the <i>mce1</i> operon conferred tolerance to vancomycin.</p><p><strong>Conclusions: </strong>Overall, this work demonstrates how drug-resistant strains experience perturbations in cell-wall production that alters their tolerance to killing by cell wall-targeting inhibitors.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"6 3","pages":"dlae086"},"PeriodicalIF":3.7,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11148391/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141247527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-30eCollection Date: 2024-06-01DOI: 10.1093/jacamr/dlae079
David Wareham, Mark Melzer
Background: New dosing regimens for ceftriaxone 4 g/24 hours and ceftazidime 3 g/12 hours are convenient for patients receiving OPAT. To date, these have not been clinically validated.
Aim: To assess the tolerability, toxicity and effectiveness of once daily ceftriaxone (4 g) and 12 hourly ceftazidime regimens (3 g twice a day) in the OPAT setting.
Patients and methods: From April 2018 until March 2023; demographic, clinical, microbiological and outcome data were collected on all adult patients discharged to a community-based OPAT team in East London.
Results: There were 487 OPAT episodes. Fifty-three (10.9%) patients received ceftriaxone 4 g once a day and 20 (4.1%) ceftazidime 3 g twice a day. In the ceftriaxone group, the commonest conditions treated were orthopaedic, neurosurgical or diabetic foot infections. OPAT was used to expedite the discharge of 45 (84.9%) patients, the remainder were admission avoidance episodes. The commonest isolate causing infection was MSSA 23 (43.4%). There were no tolerability or toxicity episodes recorded. All patients were cured and bed days saved were 1266.In the smaller twice-daily ceftazidime cohort, seven (35%) patients were treated for necrotizing otitis externa, six (30%) for bronchiectasis and six (30%) for urinary tract infections. The commonest cause of infection was P. aeruginosa, 18 (90%). One case of nephrotoxicity was recorded. All patients were cured and bed days saved were 896.
Conclusions: Regimens of ceftriaxone 4 g once a day and ceftazidime 3 g twice a day were well tolerated and highly effective. If widely adopted, these regimens will save OPAT and nursing time and enable more patients to be treated.
背景:头孢曲松 4 克/24 小时和头孢唑肟 3 克/12 小时的新给药方案对接受 OPAT 的患者很方便。目的:评估头孢曲松每日一次(4 克)和头孢唑肟每 12 小时一次(3 克,每日两次)给药方案在 OPAT 环境中的耐受性、毒性和有效性:从2018年4月至2023年3月,收集了伦敦东部社区OPAT团队出院的所有成年患者的人口统计学、临床、微生物学和结果数据:共有 487 例 OPAT 病例。53名患者(10.9%)接受了头孢曲松4克/天一次,20名患者(4.1%)接受了头孢他啶3克/天两次。在头孢曲松组中,最常见的治疗病症是骨科、神经外科或糖尿病足感染。有 45 名(84.9%)患者使用 OPAT 加快了出院速度,其余患者则避免了入院。最常见的感染分离菌是 MSSA 23 种(43.4%)。没有耐受性或毒性事件的记录。在规模较小的每日两次头孢他啶治疗组中,7 名(35%)患者因坏死性中耳炎接受治疗,6 名(30%)患者因支气管扩张接受治疗,6 名(30%)患者因尿路感染接受治疗。最常见的感染原因是铜绿假单胞菌,有 18 例(90%)。有一例肾毒性记录在案。所有患者均已治愈,节省了 896 个住院日:头孢曲松每天一次,每次 4 克;头孢唑肟每天两次,每次 3 克。如果这些方案被广泛采用,将节省 OPAT 和护理时间,使更多患者得到治疗。
{"title":"Clinical outcomes in OPAT patients treated with ceftriaxone 4 g and ceftazidime 6 g extended interval dosing regimens.","authors":"David Wareham, Mark Melzer","doi":"10.1093/jacamr/dlae079","DOIUrl":"10.1093/jacamr/dlae079","url":null,"abstract":"<p><strong>Background: </strong>New dosing regimens for ceftriaxone 4 g/24 hours and ceftazidime 3 g/12 hours are convenient for patients receiving OPAT. To date, these have not been clinically validated.</p><p><strong>Aim: </strong>To assess the tolerability, toxicity and effectiveness of once daily ceftriaxone (4 g) and 12 hourly ceftazidime regimens (3 g twice a day) in the OPAT setting.</p><p><strong>Patients and methods: </strong>From April 2018 until March 2023; demographic, clinical, microbiological and outcome data were collected on all adult patients discharged to a community-based OPAT team in East London.</p><p><strong>Results: </strong>There were 487 OPAT episodes. Fifty-three (10.9%) patients received ceftriaxone 4 g once a day and 20 (4.1%) ceftazidime 3 g twice a day. In the ceftriaxone group, the commonest conditions treated were orthopaedic, neurosurgical or diabetic foot infections. OPAT was used to expedite the discharge of 45 (84.9%) patients, the remainder were admission avoidance episodes. The commonest isolate causing infection was MSSA 23 (43.4%). There were no tolerability or toxicity episodes recorded. All patients were cured and bed days saved were 1266.In the smaller twice-daily ceftazidime cohort, seven (35%) patients were treated for necrotizing otitis externa, six (30%) for bronchiectasis and six (30%) for urinary tract infections. The commonest cause of infection was <i>P. aeruginosa</i>, 18 (90%). One case of nephrotoxicity was recorded. All patients were cured and bed days saved were 896.</p><p><strong>Conclusions: </strong>Regimens of ceftriaxone 4 g once a day and ceftazidime 3 g twice a day were well tolerated and highly effective. If widely adopted, these regimens will save OPAT and nursing time and enable more patients to be treated.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"6 3","pages":"dlae079"},"PeriodicalIF":3.7,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11138961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141179638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}